Abbott DiagnosticsDivision Human Specimen Acquisition - Transplant
C
Christopher Emery, MD
Primary Investigator
Not Recruiting
100 years or below
All
1 Location
Brief description of study
The objective of this protocol is the collection of biological specimens of human origin including EDTA whole blood of kidney transplant patients whom are being treated with immunosuppressive drug Sirolimus.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kidney transplant
-
Age: 100 years or below
-
Gender: All
Inclusion Criteria
Samples will consist of residual, de-identified specimens that are leftover following standard of care test procedures. Specimens will be EDTA whole blood selected based on matching the specimen requirements - kidney transplant patients whom are being treated with immunosuppressive drug, Sirolimus. Blood draw within the range of 15-30 ng/mL with a volume of 1.5-2 mL.
Updated on
01 Aug 2024.
Study ID: 1902587960
